Status:
TERMINATED
Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder
Lead Sponsor:
Mayo Clinic
Conditions:
Rapid Eye Movement Sleep Behavior Disorder
Parkinson Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this research is to compare the efficacy of immediate versus extended-release melatonin as a supplement affecting the sleep cycle in patients with Parkinson disease and Rapid Eye Moveme...
Detailed Description
Enrolled patients with Parkinson disease and previously diagnosed rapid eye movement sleep behavior disorder, who are being treated at Mayo Clinic in Florida, will be randomized to receive either imme...
Eligibility Criteria
Inclusion
- Diagnosed with Parkinson's disease and rapid eye movement sleep behavior disorder.
- Patient registered to Parkinson's disease database of Mayo Clinic Florida.
Exclusion
- Patients who are using other sleep aids or medications (Clonazepam).
- Patients who are not willing to undertake 1 week of washout period.
- Patients who do not sign a consent for research.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2024
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT05307770
Start Date
May 1 2022
End Date
February 1 2024
Last Update
May 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic Florida
Jacksonville, Florida, United States, 32224